Cordis, a Cardinal Health company, is a worldwide leader in the development and manufacture of interventional vascular technology with a more than 50-year history of delivering pioneering products to treat millions of patients.
Technology | Radial Access | May 15, 2019
Cordis, a Cardinal Health company, recently announced the full U.S. launch of its Radial 360 portfolio, offering a...
Technology | Vascular Closure Devices | November 05, 2018
November 2, 2018 — Cordis, a Cardinal Health company, today announced the U.S.
News | Stents Drug Eluting | February 19, 2018
February 19, 2018 — The Detroit Medical Center’s (DMC) interventional cardiology team at Heart Hospital recently beca
Feature | Vascular Closure Devices | January 22, 2018 | Dave Fornell
While manual compression remains the gold standard for hemostasis of catheterization vascular access site arteriotomi
News | Vena Cava Filters | January 02, 2018
January 2, 2018 — Osborne & Associates Law Firm, P.A., of Boca Raton, Fla., has filed suit in Palm Beach Circuit
Technology | Stents Drug Eluting | December 13, 2017
Cordis, a Cardinal Health company, and Medinol recently announced U.S. Food and Drug Administration (FDA) approval of...
News | Stents | November 10, 2017
Cordis, a Cardinal Health company, recently unveiled a comprehensive interventional cardiology portfolio, which now...
Feature | Stents | May 16, 2016
May 16, 2016 — Cardinal Health announced it has entered into a distribution agreement with Biosensors that enables Co
News | Cath Lab | October 09, 2015
October 9, 2015 — Cardinal Health is launching its expanded portfolio in the cardiova
News | Cath Lab | August 17, 2015
The global interventional cardiology devices market is expected to reach $25.16 billion by 2020, according to a new...